Wealthfront Advisers LLC Has $2.30 Million Stock Holdings in Becton, Dickinson and Company $BDX

Wealthfront Advisers LLC increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 67.5% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 13,330 shares of the medical instruments supplier’s stock after purchasing an additional 5,370 shares during the period. Wealthfront Advisers LLC’s holdings in Becton, Dickinson and Company were worth $2,296,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in BDX. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $27,000. Cornerstone Planning Group LLC boosted its position in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 99 shares in the last quarter. Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $31,000. Finally, WPG Advisers LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $36,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX stock opened at $181.49 on Thursday. The company has a fifty day moving average price of $189.14 and a 200-day moving average price of $183.39. The company has a market capitalization of $52.02 billion, a P/E ratio of 32.64, a PEG ratio of 1.44 and a beta of 0.25. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BDX shares. Royal Bank Of Canada reiterated a “sector perform” rating and set a $211.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Argus increased their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Piper Sandler reissued a “neutral” rating and issued a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $205.40.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 1,895 shares of company stock worth $358,995 over the last ninety days. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.